Roger J. M. Brüggemann
YOU?
Author Swipe
View article: Influenza-associated invasive aspergillosis in the ICU: a prospective, multicentre cohort study
Influenza-associated invasive aspergillosis in the ICU: a prospective, multicentre cohort study Open
View article: <i>In vitro</i> and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent
<i>In vitro</i> and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent Open
Background Invasive fungal diseases (IFDs) cause high morbidity and mortality among immune-compromised patients. Triazoles, which are recommended to treat IFDs, inhibit and/or are substrates for the phase 1 cytochrome P450 (CYP) pathway th…
View article: Classifying patients with invasive fungal disease: towards a unified case definition?
Classifying patients with invasive fungal disease: towards a unified case definition? Open
Management of invasive fungal disease (IFD) is increasingly challenging due to recognition of novel at-risk groups, emergence of new fungal pathogens and antifungal drug resistance. Together with the availability of new diagnostic tests an…
View article: Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients
Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients Open
Cefuroxime is a second‐generation cephalosporin widely used in the intensive care unit (ICU). ICU patients have high variability in interpatient pharmacokinetics (PK), but the extent of this variation is unclear. We performed an observatio…
View article: Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole, and Hydroxyitraconazole in Sudanese Patients With Eumycetoma
Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole, and Hydroxyitraconazole in Sudanese Patients With Eumycetoma Open
Background The first clinical trial on eumycetoma was recently conducted in Sudan, comparing oral fosravuconazole, prodrug of active ravuconazole, with the standard-of-care oral itraconazole. Building on this trial, the present study aimed…
View article: Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units—the SAFE-ICU study
Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units—the SAFE-ICU study Open
View article: P-1239. Systemic Exposure of Olorofim in Children with Invasive Fungal Infections
P-1239. Systemic Exposure of Olorofim in Children with Invasive Fungal Infections Open
Background Olorofim (OLO) is a novel antifungal active vs. Aspergillus (including azole-resistant strains), resistant moulds (e.g., Lomentospora prolificans [LoPro]), and dimorphic moulds. Treatment with OLO in children with invasive funga…
View article: The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics Open
Echinocandin drugs are the current first-line therapy for fungal infections caused by Candida spp. Most patients require once-daily intravenous (IV) administration in a hospital or outpatient setting for treatment, which may negatively imp…
View article: Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial
Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial Open
Background The EASL cystic liver disease guideline states that drug penetration at the site of infection (liver cyst) is essential for successful treatment, but pharmacokinetic (PK) data on cyst penetration are limited. Objectives This stu…
View article: Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians Open
Letermovir and maribavir have demonstrated efficacy in the prevention and treatment, respectively, of immunosuppressed patients with cytomegalovirus (CMV) infection and disease. These patients often have polypharmacy making them at risk fo…
View article: The impact of the COVID-19 pandemic and the changing landscape of CF on the cASPerCF trial: a real-world experience
The impact of the COVID-19 pandemic and the changing landscape of CF on the cASPerCF trial: a real-world experience Open
Contains fulltext : 311536.pdf (Publisher’s version ) (Open Access)
View article: Pooled Population Pharmacokinetic Analysis and Dose Recommendations for Ciprofloxacin in Intensive Care Unit Patients with Obesity
Pooled Population Pharmacokinetic Analysis and Dose Recommendations for Ciprofloxacin in Intensive Care Unit Patients with Obesity Open
Recent studies have explored the influence of obesity and critical illness on ciprofloxacin pharmacokinetics. However, variation across the subpopulation of individuals with obesity admitted to the intensive care unit (ICU) with varying re…
View article: Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study
Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study Open
Background Isavuconazole is a relatively new antifungal agent indicated for the management of various invasive fungal diseases (IFDs), including invasive aspergillosis. Information on real-world experience with isavuconazole is scarce. Thi…
View article: Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease Open
SUMMARY Fungal infections are on the rise, driven by a growing population at risk and climate change. Currently available antifungals include only five classes, and their utility and efficacy in antifungal treatment are limited by one or m…
View article: Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole
Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole Open
View article: Evaluation of the drug–drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohort
Evaluation of the drug–drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohort Open
Limited data on the clinical management of drug–drug interactions between triazoles and Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators are available. We retrospectively evaluated azole target attainment and dose adap…
View article: Development and validation of an UPLC–MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring
Development and validation of an UPLC–MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring Open
Objective To develop and validate an UPLC–MS/MS assay for simultaneous determination of the total concentration of ceftazidime, ciprofloxacin, flucloxacillin, piperacillin, tazobactam, sulfamethoxazole, N-acetyl sulfamethoxazole and trimet…
View article: Clinical presentation and outcome of invasive mould disease in paediatric patients with acute lymphoblastic leukaemia
Clinical presentation and outcome of invasive mould disease in paediatric patients with acute lymphoblastic leukaemia Open
Background: Childhood acute lymphoblastic leukaemia (ALL) cure rates have improved, but invasive mould disease (IMD) remains a life-threatening complication. Here, we evaluate the epidemiology, clinical presentation, treatment and outcome …
View article: Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action
Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action Open
Individuals with obesity are at increased risk of developing infectious diseases. Timely administration of an effective dose of an antimicrobial agent is paramount to safeguard optimal therapy. For this purpose, special patient populations…
View article: Two Dose Levels of Once-Weekly Fosravuconazole Versus Daily Itraconazole, in Combination with Surgery, in Patients with Eumycetoma in Sudan: A Randomised, Double-Blind, Phase 2, Proof-of-Concept Superiority Trial
Two Dose Levels of Once-Weekly Fosravuconazole Versus Daily Itraconazole, in Combination with Surgery, in Patients with Eumycetoma in Sudan: A Randomised, Double-Blind, Phase 2, Proof-of-Concept Superiority Trial Open
View article: Micafungin twice-a-week for prophylaxis of invasive Aspergillus infections in children with acute lymphoblastic leukaemia: A controlled cohort study
Micafungin twice-a-week for prophylaxis of invasive Aspergillus infections in children with acute lymphoblastic leukaemia: A controlled cohort study Open
View article: How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400–600 mg·h/L-Targeted Dosing
How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400–600 mg·h/L-Targeted Dosing Open
The AMIGO trial was registered in the Dutch Trial Registry [NTR6058].
View article: Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube
Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube Open
Objectives To study the isavuconazole pharmacokinetics in a real-life paediatric cohort and confirm whether the isavuconazole exposures are within the adult exposure range. Furthermore, we are the first to describe unbound isavuconazole ph…
View article: High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints Open
View article: Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies
Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies Open
ClinicalTrials.gov identifier: NCT04777058.
View article: Meta-pharmacokinetic analysis of posaconazole following dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients vs. healthy volunteers: Impact of clinical characteristics and race
Meta-pharmacokinetic analysis of posaconazole following dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients vs. healthy volunteers: Impact of clinical characteristics and race Open
Pharmacokinetics of posaconazole in patients differ considerably to those in HV, with altered Fsus that is also impacted by clinical covariates, an Ftab similar to fasted conditions in HV, and altered parameters for c…
View article: Development and validation of a bioanalytical assay for the measurement of total and unbound teicoplanin in human serum
Development and validation of a bioanalytical assay for the measurement of total and unbound teicoplanin in human serum Open
Background The glycopeptide teicoplanin is considered first-line treatment for severe infections caused by Gram-positive bacteria. Individualized treatment of teicoplanin is gaining interest. As only protein-unbound drug is pharmacological…
View article: Corrigendum to ‘The battle against fungi lessons in antifungal stewardship from COVID 19 times’ [International Journal of Antimicrobial Agents Volume 62/1 (2023) 106846]
Corrigendum to ‘The battle against fungi lessons in antifungal stewardship from COVID 19 times’ [International Journal of Antimicrobial Agents Volume 62/1 (2023) 106846] Open
View article: Oral antimicrobial agents in patients with short bowel syndrome: worth a try!
Oral antimicrobial agents in patients with short bowel syndrome: worth a try! Open
Background The use of oral antimicrobial agents in patients with short bowel syndrome (SBS) is challenging due to the changes in gastrointestinal anatomy that may result in diminished absorption and altered drug bioavailability. Prospectiv…
View article: An update on drug-drug interactions for care of the acutely ill in the era of COVID-19
An update on drug-drug interactions for care of the acutely ill in the era of COVID-19 Open
Purpose To provide key pharmacological concepts underlying drug-drug interactions (DDIs), a decision-making framework, and a list of DDIs that should be considered in the context of contemporary acutely ill patients with COVID-19. Summary …